Isentress® (raltegravir) – Expanded indication
November 22, 2017 – The FDA approved Merck’s Isentress (raltegravir) in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing ≥ 2 kg.
Download PDF
